What is the Market's View on Iovance Biotherapeutics Inc (IOVA) Stock's Price and Volume Trends Thursday?

The market has been high on Iovance Biotherapeutics Inc (IOVA) stock recently. IOVA gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Iovance Biotherapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on IOVA!

See Full IOVA Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With IOVA Stock Today?

Iovance Biotherapeutics Inc (IOVA) stock is up 5.28% while the S&P 500 is down -0.06% as of 9:37 AM on Thursday, Nov 30. IOVA has gained $0.30 from the previous closing price of $5.68 on volume of 51,068 shares. Over the past year the S&P 500 is up 14.91% while IOVA is down -2.61%. IOVA lost -$2.08 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Iovance Biotherapeutics Inc click here.

More About Iovance Biotherapeutics Inc

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. Its lead pipeline candidate, LN-145, is an adoptive cell therapy using tumor-infiltrating lymphocytes to treat patients with refractory metastatic melanoma. Click Here to get the full Stock Report for Iovance Biotherapeutics Inc stock.